Short interest for Fulcrum Therapeutics gives investors a sense of the degree to which investors are betting on the decline of Fulcrum Therapeutics's stock. Short interest data is updated every two weeks.

Fulcrum Therapeutics Stock (NASDAQ:FULC), Short Interest Report

Fulcrum Therapeutics

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AFMD

AISP

APEI

BASE

BIAF

BYSI

CERS

CETX

CMAX

CRWD

CXDO

DADA

DAVE

ENCP

FULC

GNPX

GRFS

HIPO

HSCS

IFBD

INFN

JAGX

LTRN

LYFT

MEDS

MNTS

MSTR

NEPT

NKGN

OCEA

PHUN

ROOT

RVSN

SBFM

SGHC

SOPH

TTEC

UNFI

VINC

XRTX

Shares of  United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.

Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

ALNT

AVAV

BILI

CLSK

LXEO

MBLY

PLTR

SBSW

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday.

Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday

ALLO

ALTR

ALVR

ALXO

ANSS

APGE

ARBK

ASST

ATIF

ATRA

BROG

BTDR

COMP

CYCC

DSKE

ENLV

GMBL

HUYA

IBRX

KRTX

LGCB

LITM

LTRY

MLYS

MULN

NBTX

NCPL

NMRA

NTES

NXTP

PRME

PRTC

PRZO

RKLB

RMCO

SXTP

TRML

ZJYL

Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.

Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics Inc

<p>Alico (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALCO#NASDAQ">ALCO</a>) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $(0.14) by 285.71 percent. This is a 116.05 percent increase over losses of $(1.62) per share from the same period last year.  The company reported quarterly sales of $18.113 million which missed the analyst consensus estimate of $40.600 million by 55.39 percent.  This is a 14.94 percent decrease over sales of $21.294 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

ALCO

Alico Q2 2024 Adj EPS $0.26 Beats $(0.14) Estimate, Sales $18.113M Miss $40.600M Estimate

<p>Former President <strong>Donald Trump </strong>was fined for violating a gag order in his criminal trial Monday by<a href="https://www.benzinga.com/general/politics/24/05/38646992/trump-fined-1-000-for-gag-order-violation-threatened-with-jail-time-again-by-judge-i-will-if-nec"> Judge <strong>Juan Merchan</strong>.</a></p>
<p>While speaking to reporters after the trial ended Monday, Trump appeared unphased by the recent ruling.</p>
<p><strong>What Happened: </strong>Over the last week, Trump<a href="https://www.benzinga.com/general/politics/24/04/38523639/judge-threatens-trump-with-incarceration-fines-him-for-violating-gag-order-jail-may-be-a-necessa"> has been fined $10,000</a> for 10 violations of the gag order imposed before the trial began.</p>
<p>Merchan suggested Monday that the fines weren't working and once again threatened potential jail time for the former president.</p>
<p>Trump's comments Monday suggest he could violate the gag order again.</p>
<p>"Frankly, our Constitution is far more important than jail. It's not even close. I'll do that sacrifice any day," Trump said, as <a href="https://www.nbcnews.com/politics/donald-trump/live-blog/trump-hush-money-trial-day-12-live-updates-rcna150792">shared </a>by NBC News.</p>
<p>Trump told reporters the case should be over.</p>
<p>"I thought they were finished today. They all want to keep me off the campaign trail."</p>
<p>Based on Trump's comments suggesting he won't be silenced, the trial and Trump's social media activity could be more closely monitored going forward to see if Trump will face jail time.</p>
<p>"His continued willful violations of this Court's orders threaten the administration of justice and constitute a direct attack on the rule of law. I cannot allow this to continue," Merchan said of Trump on Monday morning.</p>
<p>Merchan told the court he does not want to impose jail time on Trump.</p>
<p>"The last thing I want to do is to put you in jail. You are the former president of the United States, and possibly the next president as well. There are many reasons why incarceration is truly a last resort for you."</p>
<p>Merchan did not specify which jail Trump would be sent to. A spokesperson for Rikers Island jail said they would welcome Trump if he was sent there.</p>
<p>"The department would find appropriate housing," spokesperson<strong> Frank Dwyer</strong> said.</p>
<p><em>Related Link: <a href="https://www.benzinga.com/general/politics/24/05/38598789/trump-vs-biden-2024-election-frontrunners-tied-in-new-poll-which-candidate-gains-in-popularity-a">Trump Vs. Biden: 2024 Election Frontrunners Tied In New Poll, Which Candidate Gains In Popularity Among Voters?</a></em></p>
<p><strong>Why It's Important: </strong>The criminal trial sees<a href="https://www.benzinga.com/general/politics/24/04/38326553/trump-hush-money-trial-has-12-jurors-here-are-the-7-men-5-women-to-decide-former-presidents-fate"> Trump facing charges</a> that he falsified business records to conceal money paid to silence adult actress <strong>Stormy Daniels.</strong></p>
<p>The trial began with jury selection on April 15 and is expected to last six to eight weeks.</p>
<p>Prosecutor<strong> Joshua Steinglass</strong> estimated Monday that the District Attorney's office has two weeks left for its side of the trial. This could include having Daniels and former Trump lawyer <strong>Michael Cohen</strong> testify as key witnesses.</p>
<p>Based on the timeline, prosecution would conclude on May 21. With court not in session on May 22 or May 24, it is now likely that the trial stretches past the Memorial Day weekend.</p>
<p>Witnesses in court Monday included former Trump Organization controller <strong>Jeff McConney</strong> and former Trump Organization accounts payable supervisor <strong>Deborah Tarasoff</strong>, who remains a Trump Organization employee.</p>
<p>On Monday, the jury was shown check stubs and checks paid to Cohen.</p>
<p>Tarasoff also testified that Trump would write "VOID" on checks and send them back if he didn't approve the expenses. Invoices over $10,000 had to be approved by Trump, <strong>Donald Trump Jr. </strong>or <strong>Eric Trump</strong>, Tarasoff said Monday.</p>
<p>Each payment shown in court Monday was over the $10,000 level, which could come into play later in the trial.</p>
<p><em>Read Next: <a href="https://www.benzinga.com/general/politics/24/05/38569790/trump-uses-gag-order-fines-as-fundraising-opportunity-they-want-to-silence-me-they-think-they-ca">Trump Uses Gag Order Fines As Fundraising Opportunity: &#8216;They Want To Silence Me! They Think They Can Bleed Me Dry!&#8217;</a></em></p>
<p><em>Photo: Created with artificial intelligence on MidJourney and Zolnierek photo on Shutterstock</em></p>


Politics

Legal

Trump Unphased By Gag Order, Fines: 'Our Constitution Is Far More Important Than Jail'

<p>Caregivers are at the forefront of the <a href="https://www.benzinga.com/cannabis">medical cannabis industry</a>, tailoring treatments and providing personalized care for patients.</p>
<p>Despite their<a href="https://www.benzinga.com/markets/cannabis/22/12/30008720/what-does-it-mean-to-be-a-medical-marijuana-caregiver"> vital contributions</a>, their&nbsp;recognition and compensation often fall short. How can caregivers be fairly rewarded for their work, and what challenges do they face?</p>
<p>According to <strong>Lou Pino</strong>, a veteran event organizer and caregiver on the East Coast and founder of <a href="https://www.instagram.com/genetraders/"><strong>Gene Traders</strong></a>, an event dedicated to exchanging cannabis strains, the caregiver economy is an essential component of the industry that needs more support and understanding.</p>
<p>&ldquo;Being a caregiver comes with its share of challenges. Often, caregivers must bear the financial burden of their work, paying for everything out of their own pockets. This includes purchasing supplies, services, and equipment. It&#39;s a demanding role that requires a significant investment, both financially and emotionally,&rdquo; Pino explained.</p>
<p>Caregiving is far from free work. It&rsquo;s an endeavor that costs caregivers their own money to ensure patients receive the personalized care they need. In an exclusive interview with Benzinga, Pino shared his insights on how caregivers can navigate these challenges while also fostering innovation and diversity in <a href="https://www.benzinga.com/cannabis">cannabis cultivation</a>.</p>
<h3>Gene Traders: Exchanging Medicine</h3>
<p>&quot;In 2013, I was organizing medical events in Rhode Island to help educate people about what cannabis works best for various conditions,&quot; Pino said.</p>
<p>Recognizing the lack of resources for cultivators, he created Gene Traders as an event for exchanging knowledge and resources. &quot;The most valuable thing about Gene Traders is, yes, the access to genetics, but it&#39;s the conversation, months with just a few sentences,&quot; he said.</p>
<p>Gene Traders provides access to genetics and fosters collaboration among cultivators. These<a href="https://www.youtube.com/@genetradersofficial"> intimate cannabis events</a>, typically gathering around 300 to 500 people in a single day, are lively hubs where cultivators and breeders showcase their plants, set up informative booths&nbsp;and share insights on growing, crossing&nbsp;and breeding.</p>
<p>It&#39;s a vibrant scene, filled with experts eager to exchange knowledge and celebrate the <a href="https://www.benzinga.com/topic/cannabis-branding">craft of cannabis </a>cultivation.&nbsp;&quot;The conversations and collaborations are more important than just buying genetics,&quot; he said. The event&#39;s exchange of knowledge is invaluable, helping growers save time and improve their practices.</p>
<p>One reason why events like Gene Traders are important is that they facilitate the growth of whole plants for medical patients.</p>
<p>The entourage effect refers to the synergistic interaction between the <a href="https://www.benzinga.com/markets/cannabis/23/03/31197289/what-are-cannabinoids-their-types-and-effects">various compounds in cannabis</a>, including cannabinoids, terpenes, and flavonoids, which together create a therapeutic effect greater than the sum of their parts.</p>
<p>This effect is vital for the endocannabinoid system, which plays a role in regulating various bodily functions, including pain, mood, and appetite. &ldquo;Tailored treatments using whole-plant cannabis are often more effective for medical patients, as they can address <a href="https://www.benzinga.com/markets/cannabis/23/12/36394288/cannabis-2024-experts-weigh-in-what-to-expect-from-dc-and-business-outlook-exciting-point-in-tim">specific needs </a>and conditions more precisely than isolated <a href="https://www.benzinga.com/markets/cannabis/20/10/17942676/most-abundant-cannabinoids">compounds</a>,&rdquo; Pino continued.</p>
<p>By fostering an environment where cultivators can share knowledge and collaborate, Gene Traders helps to ensure that patients have access to the best possible treatments.</p>
<h3>The Caregiver Gene Pool: Fostering Innovation</h3>
<p>Caregivers play a critical role in expanding the gene pool through sharing and collaboration at events like Gene Traders.&nbsp;&quot;Without the caregiver or the home market, it would be very difficult for us to get new names because it&#39;s too expensive to hunt through genetics in a commercial facility.&quot;</p>
<p>The innovative environment fostered by caregivers leads to distinctive cannabis profiles that enrich the<a href="https://www.benzinga.com/cannabis"> market</a>.</p>
<p>Oino explained that developing different genetic profiles to treat different conditions &quot;is highly dependent on the resources home cultivators have.&quot;</p>
<p>Depending on these resources, caregivers, and growers can contribute to the<a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36268367/u-s-cannabis-market-premium-products"> development of premium, unique cannabis</a> profiles that stand out in the market.</p>
<p>By nurturing a diverse gene pool, caregivers who grow their own</p>
<p>contribute to a rich tapestry of cannabis varieties, ensuring the industry continues to evolve and cater to diverse consumer needs.</p>
<h3>Access To The Market For Caregivers</h3>
<p>According to Pino, states like Maine, Rhode Island, and <a href="https://www.benzinga.com/topic/massachusetts-cannabis">Massachusetts</a> have favorable caregiver laws, while states like <a href="https://www.benzinga.com/topic/connecticut-cannabis">Connecticut</a> and <a href="https://www.benzinga.com/topic/new-york-cannabis">New York</a> are more restrictive.</p>
<p>&quot;For example, Michigan allows caregivers to grow up to 72 plants,&quot; Pino pointed out. However, in Connecticut&nbsp;the limit is just &quot;three in veg and three in flower,&quot; which restricts caregivers&#39; ability to experiment and develop new strains.</p>
<p>Pino highlighted the importance of compensating caregivers fairly.</p>
<p>He mentioned that some states allow caregivers to sell their surplus to <a href="https://www.benzinga.com/topic/cannabis-branding">dispensaries</a>, which helps medical markets flourish. He said, &quot;If caregivers can pass testing, they should be able to sell to the medical market.&quot;</p>
<p>Pino also noted how government involvement and red tape can hinder cultivators from getting their products to market​.</p>
<p>Pino suggested a straightforward approach.&nbsp;&quot;Once you <a href="https://www.benzinga.com/markets/cannabis/23/09/34122583/oregon-court-halts-zero-tolerance-aspergillus-mold-testing-cannabis-cultivators-find-respite">pass testing</a>, you should be able to pull out your income, pay taxes, and keep moving forward.&nbsp;This practical solution supports caregivers and contributes to a vibrant cannabis industry.&quot;</p>
<p><em>Photo: AI-Generated Image.&nbsp;</em></p>


Cannabis

Education

Health Care

Exclusives

Interview

General

The Cannabis Caregiver Economy: Why These Workers Deserve Market Access And How States Can Help

<p>A close race between<strong> President Joe Biden </strong>and former President <strong>Donald Trump</strong> is anticipated by many for the <a href="https://www.benzinga.com/topic/2024-election">2024 presidential election.</a></p>
<p>While most election polls predict a close race between the two candidates, a recent poll shows a sizable lead for one candidate.</p>
<p><strong>What Happened</strong>: A new poll from <strong>Rasmussen Reports</strong> showed one 2024 presidential candidate with a 10-point lead, an outlier from other election polls and current <a href="https://www.benzinga.com/general/sports-betting/24/04/38417836/trump-and-biden-get-ready-2024-election-betting-odds-point-to-major-showdown">betting odds for the election.</a></p>
<p>The new Rasmussen <a href="https://www.rasmussenreports.com/public_content/politics/biden_administration/election_2024_trump_now_10_over_biden">poll </a>had Donald Trump at 46% and Joe Biden at 36%. <strong>Robert F. Kennedy Jr.</strong> came in at 9% in the latest poll. The remaining people polled chose another candidate or said they were undecided.</p>
<p><strong>When the poll was expanded to more candidates, the Rasmussen results were as follows:</strong></p>
<p><strong>Donald Trump:</strong> 48%</p>
<p><strong>Joe Biden:</strong> 36%</p>
<p><strong>Robert F. Kennedy Jr.</strong>: 8%</p>
<p><strong>Cornel West</strong>: 1%</p>
<p><strong>Jill Stein:</strong> 1%</p>
<p>The latest Rasmussen poll marked an improvement for Trump who was at 44% in April and a drop for Biden who was at 38%.</p>
<p><em>Related Link: <a href="https://www.benzinga.com/general/politics/24/05/38646992/trump-fined-1-000-for-gag-order-violation-threatened-with-jail-time-again-by-judge-i-will-if-nec">Trump Fined $1,000 For Gag Order Violation, Judge Threatens Jail Time Again: &#8216;Incarceration Is Truly A Last Resort&#8217;</a></em></p>
<p><strong>Why It's Important</strong>: The Republican-leaning Rasmussen was called into question when the latest poll results were shared. Many were quick to point out that a double-digit lead at this point in the election cycle is an extreme outlier.</p>
<p>One publication <a href="https://nymag.com/intelligencer/article/trump-vs-biden-polls-dont-be-fooled-by-outliers.html">noted</a> the last time a president won the national popular vote by more than 10 points it was Ronald Reagan 30 years ago when he won 49 of the 50 states.</p>
<p>The Washington Post <a href="https://www.washingtonpost.com/politics/2024/03/08/rasmussen-538-polling/">shared </a>earlier this year that Rasmussen Reports was dropped from poll aggregation platform FiveThirtyEight, which is owned by ABC News.</p>
<p>Rasmussen has spoken out in support of its polling and said that it was unfairly removed from the polling aggregate site.</p>
<p>"Dear ABC, the presidential race ISN'T tight. We have Trump up 12, not 2. Oh, and ABC kicked us out of the 538 aggregate because we wouldn't disclose proprietary info," Rasmussen <a href="https://twitter.com/Rasmussen_Poll/status/1787485122922414260">tweeted</a>.</p>
<p>A tweet that shared political polling data saw many comments laughing at the Rasmussen report and some calling for Community Notes, the X tool that shares reasons why posts are inaccurate.</p>
<p>Biden won the popular vote 51.3% to Trump's 46.9% in the 2020 presidential election. Trump won the electoral college vote and <strong>Hillary Clinton </strong>won the popular vote at 48.2% to Trump's 46.1% in the 2016 election.</p>
<p>It is five months before voters head to the polls to select the next president. Until then, election polls will serve as a guide to how likely each candidate is to win.</p>
<p><em>Read Next: <a href="https://www.benzinga.com/news/24/05/38632860/trump-vs-biden-one-candidate-gains-significant-ground-among-this-demographic-in-tightly-contested-ra">Trump Vs. Biden: One Candidate Gains Significant Ground Among This Demographic In Tightly Contested Race</a></em></p>
<p><em>Photo: Shutterstock</em></p>


Trump Vs. Biden: Former President Has 10-Point Lead In New 2024 Election Poll, Some Cry Foul Over Accuracy

<p>Gaia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIA#NASDAQ">GAIA</a>) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 16.67 percent increase over losses of $(0.06) per share from the same period last year.  The company reported quarterly sales of $21.693 million which beat the analyst consensus estimate of $21.400 million by 1.37 percent.  This is a 10.41 percent increase over sales of $19.647 million the same period last year.</p>


GAIA

Gaia Q1 2024 GAAP EPS $(0.05), Inline, Sales $21.693M Beat $21.400M Estimate

<p>Every new Apple Watch model not only steps up its game with more features but also syncs seamlessly with an ever-expanding universe of third-party apps. These apps are your sidekicks for everything from tracking steps to monitoring your heart rate, answering queries, and navigating spaces, making life smoother without constantly fishing for your phone.</p>
<p>If you&#8217;ve invested in an Apple Watch, or splurged on the fancier Apple Watch Ultra, you&#8217;re well aware of its prowess. It&#8217;s not just about keeping tabs on your fitness or reminding you to pause for a breather — this gadget stands out as a top-tier health-tech tool. So here&#8217;s our pick of 10 apps that you must have on your Apple Watch:</p>
<h3 class="wp-block-heading">Waterminder</h3>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="577" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06094827/Waterminder-app-1024x577.jpg" alt="WaterMinder is a water drinking reminder app that helps you stay hydrated throughout the day with personalized reminders. Image credit: Funn Media" class="wp-image-324057" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06094827/Waterminder-app-1024x577.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06094827/Waterminder-app-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06094827/Waterminder-app-768x433.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06094827/Waterminder-app.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">WaterMinder is a water-drinking reminder app that helps you stay hydrated throughout the day with personalized reminders. Image credit: Funn Media</figcaption></figure></p>
<p>Staying hydrated is crucial, yet often overlooked. The Waterminder app syncs with your iPhone&#8217;s Health app to calculate your daily water needs and nudges you throughout the day to meet your hydration goal. It even tracks the water content from beverages like coffee and juice, helping you make healthier choices effortlessly.</p>
<h3 class="wp-block-heading">iTranslate Converse</h3>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095022/itranslate-converse-1024x576.jpeg" alt="The iTranslate Converse app translates real-time conversations on your Apple Watch. Image credit: iTranslate Converse" class="wp-image-324065" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095022/itranslate-converse-1024x576.jpeg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095022/itranslate-converse-300x169.jpeg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095022/itranslate-converse-768x432.jpeg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095022/itranslate-converse.jpeg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">The iTranslate Converse app translates real-time conversations on your Apple Watch. Image credit: iTranslate Converse</figcaption></figure></p>
<p>Breaking language barriers becomes simple with iTranslate Converse. This app listens and translates between two languages in real-time, enabling seamless conversation with someone who speaks a different language. It displays and speaks the translation on your Apple Watch, making communication easy and natural.</p>
<h3 class="wp-block-heading">Just Press Record</h3>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095213/just-press-record-1024x576.jpg" alt="The Just Press Record app lets you quickly start, stop, and listen to recordings, right from your wrist. Image credit: Just Press Record" class="wp-image-324067" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095213/just-press-record-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095213/just-press-record-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095213/just-press-record-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095213/just-press-record.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">The Just Press Record app lets you quickly start, stop, and listen to recordings, right from your wrist. Image credit: Just Press Record</figcaption></figure></p>
<p>For quick audio recordings, Just Press Record delivers high functionality with minimal fuss. This app lets you start, stop, and playback recordings directly from your Apple Watch, ideal for capturing thoughts or conversations when your iPhone isn&#8217;t handy.</p>
<h3 class="wp-block-heading">Calm</h3>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095512/calm-apple-watch-1024x576.jpg" alt="The Calm app offers guided meditations, breathing exercises, mindful movement sessions, guided stretching and more on your wrist. Image credit: Calm" class="wp-image-324070" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095512/calm-apple-watch-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095512/calm-apple-watch-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095512/calm-apple-watch-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095512/calm-apple-watch.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">The Calm app offers guided meditations, breathing exercises, mindful movement sessions, guided stretching and more on your wrist. Image credit: Calm</figcaption></figure></p>
<p>Calm brings a suite of meditation and relaxation tools to your wrist. Start your day with a 10-minute session, tackle anxiety with Emergency Calm, or unwind with a Sleep Story, all accessible from your Apple Watch. These activities also contribute to filling your daily activity rings.</p>
<h3 class="wp-block-heading">Spotify</h3>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095619/spotify-apple-watch-1024x576.jpg" alt="Even if you use Spotify's free version, you can control Spotify playlists from your watch with the app. Image credit: Spotify" class="wp-image-324072" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095619/spotify-apple-watch-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095619/spotify-apple-watch-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095619/spotify-apple-watch-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095619/spotify-apple-watch.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Even if you use Spotify's free version, you can control Spotify playlists from your watch with the app. Image credit: Spotify</figcaption></figure></p>
<p>Music lovers can enjoy Spotify directly from their Apple Watch. Premium users can download tracks for offline listening, while free users can control music playback and stream through Bluetooth headphones or smart speakers at home.</p>
<h3 class="wp-block-heading">Audible</h3>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095718/audible-apple-watch-app-1024x576.jpg" alt="The Audible app will sync with the iPhone app to pick up right where you left off, so you won't lose your spot. Image credit: Audible" class="wp-image-324075" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095718/audible-apple-watch-app-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095718/audible-apple-watch-app-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095718/audible-apple-watch-app-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095718/audible-apple-watch-app.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">The Audible app will sync with the iPhone app to pick up right where you left off, so you won&#8217;t lose your spot. Image credit: Audible</figcaption></figure></p>
<p>For book enthusiasts, Audible makes it easy to immerse yourself in audiobooks right from your wrist. Whether streaming over LTE or listening offline, the Audible app for Apple Watch keeps your place synced with your iPhone app.</p>
<h3 class="wp-block-heading">Nike Run Club</h3>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095826/apple-watch-nike-1024x576.jpg" alt="The Nike Run Club app logs stats like distance, pace, splits, heart rate and more. Image credit: Nike" class="wp-image-324079" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095826/apple-watch-nike-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095826/apple-watch-nike-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095826/apple-watch-nike-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06095826/apple-watch-nike.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">The Nike Run Club app logs stats like distance, pace, splits, heart rate and more. Image credit: Nike</figcaption></figure></p>
<p>Enhance your runs with the Nike Run Club app, which tracks detailed running metrics and offers audio-guided runs and custom coaching plans. It's perfect for both casual joggers and serious runners looking to achieve their personal best.</p>
<h3 class="wp-block-heading">Apple Maps</h3>
<p><figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="1000" height="667" src="https://editorial-assets.benzinga.com/wp-content/uploads/2023/07/21070752/Apple-Watch.jpg" alt="The Apple Maps app works much better than the Google Maps app on the Apple Watch. Image credit: Shutterstock" class="wp-image-72433" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2023/07/21070752/Apple-Watch.jpg 1000w,https://editorial-assets.benzinga.com/wp-content/uploads/2023/07/21070752/Apple-Watch-300x200.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2023/07/21070752/Apple-Watch-768x512.jpg 768w" sizes="(max-width: 1000px) 100vw, 1000px" /><figcaption class="wp-element-caption">The Apple Maps app works much better than the Google Maps app on the Apple Watch. Image credit: Shutterstock</figcaption></figure></p>
<p>While you might prefer Google Maps on your iPhone, Apple Maps excels on the Apple Watch. Ask Siri for directions, and get clear, step-by-step navigation with alerts for upcoming turns, all from your wrist.</p>
<h3 class="wp-block-heading">Phone Buddy</h3>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06100107/phone-buddy-apple-watch-app-1024x576.jpg" alt="The Phone Buddy app uses Bluetooth to monitor how far apart your iPhone and Apple Watch are. Image credit: Phone Buddy" class="wp-image-324097" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06100107/phone-buddy-apple-watch-app-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06100107/phone-buddy-apple-watch-app-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06100107/phone-buddy-apple-watch-app-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/06100107/phone-buddy-apple-watch-app.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">The Phone Buddy app uses Bluetooth to monitor how far apart your iPhone and Apple Watch are. Image credit: Phone Buddy</figcaption></figure></p>
<p>Never forget your iPhone again with Phone Buddy, which alerts you if you move too far from your phone. It&#8217;s particularly useful for those moments when you rush out the door and leave your phone behind.</p>
<h3 class="wp-block-heading">Lifeline 2</h3>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/01/18090850/Apple-Watch-1024x576.jpg" alt="Lifeline 2 is a choose-your-own-adventure game in which you receive messages on your Apple Watch and select a response to move the story forward. Image credit:  Apple" class="wp-image-186216" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/01/18090850/Apple-Watch-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/01/18090850/Apple-Watch-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/01/18090850/Apple-Watch-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/01/18090850/Apple-Watch-1536x864.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/01/18090850/Apple-Watch.jpg 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Lifeline 2 is a choose-your-own-adventure game in which you receive messages on your Apple Watch and select a response to move the story forward. Image credit:  Apple</figcaption></figure></p>
<p>For gaming on the go, Lifeline 2 offers an engaging choose-your-own-adventure experience that unfolds in real-time on your Apple Watch. It's a unique game that fits the Apple Watch&#8217;s interface perfectly, providing entertainment at your fingertips.</p>


Tech

Unleash The Power Of Your Apple Watch: Discover The Top 10 Apps You Can't Afford To Miss This Year

<p>Otter Tail (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTTR#NASDAQ">OTTR</a>) reported quarterly earnings of $1.77 per share which beat the analyst consensus estimate of $1.46 by 21.23 percent. This is a 18.79 percent increase over earnings of $1.49 per share from the same period last year.  The company reported quarterly sales of $347.068 million which missed the analyst consensus estimate of $353.663 million by 1.86 percent.  This is a 2.36 percent increase over sales of $339.081 million the same period last year.</p>


OTTR

Otter Tail Q1 2024 GAAP EPS $1.77 Beats $1.46 Estimate, Sales $347.068M Miss $353.663M Estimate

<p>Masonite International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOOR#NYSE">DOOR</a>) reported quarterly earnings of $1.29 per share which missed the analyst consensus estimate of $2.03 by 36.45 percent. This is a 31.38 percent decrease over earnings of $1.88 per share from the same period last year.  The company reported quarterly sales of $668.339 million which missed the analyst consensus estimate of $721.176 million by 7.33 percent.  This is a 7.94 percent decrease over sales of $725.984 million the same period last year.</p>


DOOR

Masonite International Q1 2024 Adj EPS $1.29 Misses $2.03 Estimate, Sales $668.339M Miss $721.176M Estimate

<p>For full year 2024, Ring continues to expect total capital spending of&nbsp;$135 million&nbsp;to&nbsp;$175 million.&nbsp;The Company forecasts full year 2024 oil sales volumes of 12,600 to 13,300 Bo/d compared with full year 2023 oil sales volumes of 12,548 Bo/d, with the mid-point of&nbsp;guidance&nbsp;reflecting a&nbsp;3%&nbsp;increase.</p>
<p>Ring expects&nbsp;second quarter&nbsp;2024 sales volumes of 13,000 to 13,400 Bo/d and 18,500 to 19,100 Boe/d (70%&nbsp;oil,&nbsp;15%&nbsp;natural gas, and&nbsp;15%&nbsp;NGLs). The Company is targeting total capital expenditures in the&nbsp;second quarter&nbsp;of 2024 of&nbsp;$37 million&nbsp;to&nbsp;$42 million.</p>


Guidance

Ring Energy Reiterates Full Year 2024 Guidance

PTEN

Patterson-UTI Reports An Average Of 116 Drilling Rigs Operating In US During April

<p>This award is the latest of a series of contracts related to SDA&#39;s Transport Layer going back to Redwire&#39;s delivery of its first&nbsp;Link 16<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fredwirespace.com%2Fnewsroom%2Fredwire-successfully-delivers-tranche-0-l-band-helical-antenna-system-for-sda-transport-layer%2F%3Frdwj%3D47003-47058-31687-50414&amp;esheet=53975711&amp;newsitemid=20240506251712&amp;lan=en-US&amp;anchor=Link+16+antennas+for+Tranche+0+in+2020&amp;index=4&amp;md5=a3a27aeed5fab8932d573ec834d0dd11"> </a>antennas for Tranche 0 in 2020. The company was also&nbsp;selected to provide RF hardware and antennas&nbsp;for Tranche 1 satellites. Redwire has delivered 48 Link-16 antennas to date for Tranche-1.</p>


Contracts

Redwire Says Selected by Rocket Lab To Provide Antennas For Space Development Agency's Transport Layer Tranche 2 Satellite Constellation

<p>Air Transport Services Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.11 by 45.45 percent. This is a 55.56 percent decrease over earnings of $0.36 per share from the same period last year.  The company reported quarterly sales of $485.517 million which missed the analyst consensus estimate of $497.520 million by 2.41 percent.  This is a 3.11 percent decrease over sales of $501.095 million the same period last year.</p>


ATSG

Air Transport Services Gr Q1 2024 Adj EPS $0.16 Beats $0.11 Estimate, Sales $485.517M Miss $497.520M Estimate

<div>For the&nbsp;second quarter, revenue outlook at the mid-point would represent growth of approximately&nbsp;20%&nbsp;year-over-year. It expects&nbsp;second quarter&nbsp;non-GAAP operating margin to be approximately&nbsp;11.0%.</div>


SEMR

Semrush Expects Q2 Revenue Of $89.1M-$90.1M (Est $88.917M), Raises FY24 Revenue Forecast From $364M-$368M To $366M-$369M (Est $366.22M)

<p>Ring Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/REI#AMEX">REI</a>) reported quarterly earnings of $0.10 per share which met the analyst consensus estimate. This is a 23.08 percent decrease over earnings of $0.13 per share from the same period last year.  The company reported quarterly sales of $94.503 million which beat the analyst consensus estimate of $91.158 million by 3.67 percent.  This is a 7.29 percent increase over sales of $88.083 million the same period last year.</p>


Ring Energy Q1 2024 GAAP EPS $0.10, Inline, Sales $94.503M Beat $91.158M Estimate

<p>Due to the reduced Adjusted EBITDA&nbsp;guidance, the Company now expects 2024 operating cash flow to be approximately&nbsp;$225 million&nbsp;compared to the previous&nbsp;outlook&nbsp;of approximately&nbsp;$250 million.&nbsp;</p>


JELD

JELD-WEN Lowers 2024 Revenue Guidance From $4.0B-$4.3B To $3.9B-$4.1B, Est $4.148B

<p>SEMrush Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.02 by 50 percent. This is a 114.29 percent increase over losses of $(0.07) per share from the same period last year.  The company reported quarterly sales of $85.812 million which beat the analyst consensus estimate of $85.010 million by 0.94 percent.  This is a 21.08 percent increase over sales of $70.870 million the same period last year.</p>


SEMrush Hldgs Q1 2024 GAAP EPS $0.01 Misses $0.02 Estimate, Sales $85.812M Beat $85.010M Estimate

JPMorgan Chase Reports Visa's Acceptance Of Class B-1 Common Stock

<p>Black Stone Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSM#NYSE">BSM</a>) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.35 by 22.86 percent.  The company reported quarterly sales of $105.493 million which missed the analyst consensus estimate of $120.341 million by 12.34 percent.  This is a 39.57 percent decrease over sales of $174.578 million the same period last year.</p>


Black Stone Minerals Q1 2024 GAAP EPS $0.27 Misses $0.35 Estimate, Sales $105.493M Miss $120.341M Estimate

<p>JELD-WEN Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.18 by 16.67 percent. This is a 16 percent decrease over earnings of $0.25 per share from the same period last year.  The company reported quarterly sales of $959.100 million which missed the analyst consensus estimate of $964.550 million by 0.56 percent.  This is a 11.28 percent decrease over sales of $1.081 billion the same period last year.</p>


JELD-WEN Holding Q1 2024 Adj EPS $0.21 Beats $0.18 Estimate, Sales $959.100M Miss $964.550M Estimate

<p>Claros Mortgage Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMTG#NYSE">CMTG</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $0.20 by 160 percent. This is a 141.38 percent decrease over earnings of $0.29 per share from the same period last year.  The company reported quarterly sales of $58.825 million which missed the analyst consensus estimate of $75.530 million by 22.12 percent.  This is a 14.87 percent decrease over sales of $69.102 million the same period last year.</p>


CMTG

Claros Mortgage Trust Q1 2024 Adj EPS $(0.12) Misses $0.20 Estimate, Sales $58.825M Miss $75.530M Estimate

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Fulcrum Therapeutics (FULC – Research Report), Ligan...

Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (FULC), Ligand Pharma (LGND) and Alphatec Holdings (ATEC)

Oppenheimer analyst Matthew Biegler maintained a Buy rating on Fulcrum Therapeutics (FULC – Research Report) today and set a price target of $16.00...

Oppenheimer Sticks to Their Buy Rating for Fulcrum Therapeutics (FULC)

In a report released on February 27, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Fulcrum Therapeutics (FULC – Research Report)...

Strong Buy Rating for Fulcrum Therapeutics Amidst Promising Clinical Progress and Financial Stability

The 70 rating InvestorsObserver gives to Fulcrum Therapeutics Inc (FULC)  stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 82 percent of stocks in the Biotechnology industry, FULCâ€&#x2122;s 70 overall rating means the stock scores better than 70 percent of all stocks. FULC has an Overall

Is Fulcrum Therapeutics Inc (FULC) a Good Choice in Biotechnology Wednesday?

Fulcrum hits 52-week high as CEO buys shares

Fulcrum Therapeutics appoints Patrick Horn as permanent Chief Medical Officer

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arcutis Biotherapeutics (ARQT – Research Report), Fu...

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)

Fulcrum Therapeutics Inc (FULC) is around the top of the Biotechnology industry according to InvestorsObserver. FULC received an overall rating of 65, which means that it scores higher than 65 percent of all stocks. Fulcrum Therapeutics Inc also achieved a score of 77 in the Biotechnology industry, putting it above 77 perc

Should Biotechnology Stock Fulcrum Therapeutics Inc (FULC) Be in Your Portfolio Friday?

A rating of 84 puts Fulcrum Therapeutics Inc (FULC) near the top of the Healthcare sector according to InvestorsObserver.Fulcrum Therapeutics Inc's score of 84 means that it ranks higher than 84% of stocks in the sector. In addition, its overall score of 83 ranks it higher than 83% of all stocks. FULC has an Overall Score

Is Fulcrum Therapeutics Inc (FULC) Stock a Bad Value Tuesday?

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result. And poor results can happen to anybody, big or small.</p>



<p>Indeed, the prospect of being on the wrong end of a giant killing adds significant risk to market participants. So, as a calculated approach, since you&rsquo;re going to be taking huge risks anyways, you might as well go for ideas with the substantial upside return potential. On that note, below are under-$10 biotech stocks to consider.</p>



<h2>Actinium Pharmaceuticals (ATNM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p>Based in New York, <strong>Actinium Pharmaceuticals</strong> (NYSEAMERICAN:<a href="https://investorplace.com/stock-quotes/atnm-stock-quote/"><strong>ATNM</strong></a>) is a clinical-stage biopharmaceutical company <a href="https://finance.yahoo.com/quote/ATNM/profile">developing targeted radiotherapies</a>. Specifically, it delivers cancer-killing radiation to treat patients with high unmet medical needs. Actinium features a product candidate which is in Phase 3 clinical trials for elderly relapsed or refractory acute myeloid leukemia.</p>



<p>Currently, Wall Street analysts rate ATNM a <a href="https://www.tipranks.com/stocks/atnm/forecast">unanimous strong buy</a>. Their average price target stands at $30.50, implying nearly 239% upside potential. Notably, the high-side estimate calls for a price of $50. Among the covering experts, they&rsquo;re anticipating fiscal 2024 loss per share to land at $1.73. Though not profitable, this forecast represents an improvement over last year&rsquo;s loss of $1.83.</p>



<p>At the moment, Actinium is practically a pre-revenue enterprise. If we want to dive into the minutia, it did post sales of $81,000 last year. However, it&rsquo;s not projected to generate any sales this year. However, in fiscal 2025, analysts are looking for sales of $72.82 million. Therefore, it&rsquo;s one of the more promising ideas for under-$10 biotech stocks to consider.</p>



<h2>Outlook Therapeutics (OTLK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/03/eyes-stock-1-300x169.png" alt="Image of a woman with a digital display over her eye."><div>Source: Who is Danny / Shutterstock.com</div></div><p>Headquartered in Iselin, New Jersey, <strong>Outlook Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/otlk-stock-quote/"><strong>OTLK</strong></a>) operates as a clinical-stage biopharmaceutical company. It focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate, <a href="https://ir.oncobiologics.com/news-releases/news-release-details/outlook-therapeuticsr-receives-european-union-positive-chmp#:~:text=ONS%2D5010%2FLYTENAVA%E2%84%A2%20is,AMD%20and%20other%20retinal%20diseases.">ONS-5010 for the treatment of wet age-related macular degeneration</a> and other retina diseases is currently in Phase 3 clinical trials.</p>



<p>Presently, Wall Street rates OTLK a <a href="https://www.tipranks.com/stocks/otlk/forecast">unanimous strong buy</a>. Further, the average price target lands at $40.20, implying 362% growth potential. Moreover, the highest price target hits $60, emphasizing the broad enthusiasm for this biotech firm. For fiscal 2024, experts see the company posting a loss per share of $3.28. Yes, it&rsquo;s in the red but it&rsquo;s an improvement over last year&rsquo;s $4.80 below breakeven.</p>



<p>However, the top line is where things get exciting. Analysts see revenue reaching $240,000, with the high-side estimate hitting $1.43 million. Last year, Outlook did not generate any sales. Even better, forecasts call for fiscal 2025 sales to hit $13.09 million. Thus, it&rsquo;s a compelling idea for under-$10 biotech stocks.</p>



<h2>Recursion Pharmaceuticals (RXRX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/07/rxrx1600-300x169.png" alt="Recursion Pharmaceuticals (RXRX) website displayed on a modern smartphone"><div>Source: Piotr Swat / Shutterstock.com</div></div><p>A clinical-stage biotech firm, <strong>Recursion Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/rxrx-stock-quote/"><strong>RXRX</strong></a>) engages in integrating technological innovations across biology, automation, data science and engineering to industrialize drug discovery. One of its lead product candidates, a therapeutic for treating cerebral cavernous malformation, is currently in Phase 2 clinical trials.</p>



<p>Per analysts, RXRX stock represents a <a href="https://www.tipranks.com/stocks/rxrx/forecast">moderate buy</a>. Further, the average price target lands at $17, implying over 102% upside potential. For the current fiscal year, experts anticipate Recursion to post a loss per share of $1.72. Admittedly, that&rsquo;s worse than last year&rsquo;s red ink of $1.58. That said, the most optimistic assessment calls for a loss of $1.49.</p>



<p>On the top line, the news becomes substantially more favorable. Analysts are looking for sales of $56.16 million,. That would be up 26% from last year&rsquo;s tally of $44.58 million. For fiscal 2025, they&rsquo;re looking for revenue of $88.43 million, up 57.5% against projected 2024 sales. If you like to speculate, RXRX belongs on your radar of under-$10 biotech stocks to buy.</p>



<h2>Ocular Therapeutix (OCUL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/12/eye-1600-300x169.jpg" alt="A close-up of someone's eye"><div>Source: Shutterstock</div></div><p>Headquartered in Bedford, Massachusetts, <strong>Ocular Therapeutix</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocul-stock-quote/"><strong>OCUL</strong></a>) is a biopharma company focused on the formulation, development and commercialization of therapies for diseases and conditions of the eye. It uses a bioresorbable hydrogel-based formulation technology. It&rsquo;s developing an <a href="https://www.ophthalmologytimes.com/view/ocular-therapeutix-inc-screens-first-3-patients-in-phase-3-sol-1-trial">axitinib intravitreal implant that is in Phase 3 trials</a> for the treatment of wet age-related macular degeneration.</p>



<p>Per Wall Street analysts, OCUL rates as a <a href="https://www.tipranks.com/stocks/ocul/forecast">consensus strong buy</a>. On average, the price target stands at $16.33, implying over 104% upside potential. Further, the most optimistic target calls for a price of $24. Covering experts see fiscal 2024&rsquo;s loss per share coming in at 83 cents. While not a profitable enterprise, this figure would represent a conspicuous improvement over last year&rsquo;s loss of $1.02.</p>



<p>On the top line, analysts anticipate revenue to hit $68.34 million. If so, we&rsquo;re talking about year-over-year growth of 16.9% from last year&rsquo;s haul of $58.44 million. For fiscal 2025, they&rsquo;re looking for sales of $85.9 million. Even better, the highest target seeks a top-line print of $116 million. Overall, it&rsquo;s a compelling take for under-$10 biotech stocks.</p>



<h2>Marinus (MRNS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div><p>Based in Radnor, Pennsylvania, <strong>Marinus</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrns-stock-quote/"><strong>MRNS</strong></a>) is a pharmaceutical company focusing on the development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. Its <a href="https://ir.marinuspharma.com/news/news-details/2024/Marinus-Pharmaceuticals-Reports-Preliminary-Fourth-Quarter-and-Full-Year-2023-ZTALMY-Net-Product-Revenue-and-Provides-Business-Update/default.aspx">main product is Ztalmy</a>, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations.</p>



<p>Presently, covering experts rate MRNS stock as a <a href="https://www.tipranks.com/stocks/mrns/forecast#">consensus strong buy</a>. The average price target lands at $19.78, implying 163% growth potential. Also, the highest target calls for a price per share of $28. For the current fiscal year, analysts are looking for a loss per share of $2.36. While the bottom line is printed in red ink, the projected figure would be an improvement over last year&rsquo;s loss of $2.63 per share.</p>



<p>On the top line, analysts are looking for revenue of $40.53 million. That would imply YOY growth of nearly 31% from last year&rsquo;s haul of $30.99 million. Further, the most optimistic target seeks a sales print of $54.3 million. For fiscal 2025, revenue could rise to $66.62 million. Based on the growth potential, MRNS is one of the under-$10 biotech stocks to consider.</p>



<h2>Fulcrum Therapeutics (FULC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/medical-biotech-stocks1600-300x169.png" alt="Healthcare business graph data and growth, Medical examination and doctor analyzing medical report network connection on tablet screen. VANI stock"><div>Source: PopTika / Shutterstock.com</div></div><p>Calling Cambridge, Massachusetts home, <strong>Fulcrum Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/fulc-stock-quote/"><strong>FULC</strong></a>) is a clinical-stage biopharma focusing on the development of products for improving the lives of patients suffering from genetically defined diseases. In particular, it seeks to address conditions with high unmet medical needs. It features a small-molecule-based candidate that&rsquo;s in Phase 3 trials for the treatment of muscular dystrophy.</p>



<p>Presently, Wall Street analysts rate FULC a <a href="https://www.tipranks.com/stocks/fulc/forecast">consensus strong buy</a> with a $13.29 average price target. That implies over 77% upside potential. Further, the most optimistic forecast calls for a price per share of $17. For fiscal 2024, covering experts are anticipating a loss per share of $1.75. Admittedly, that&rsquo;s an expansion of last year&rsquo;s red ink of $1.59 per share.</p>



<p>It also doesn&rsquo;t immediately get better on the top line, with analysts projecting sales of $1.92 million. Conspicuously, that&rsquo;s 31.6% off the pace of last year&rsquo;s tally of $2.81 million. Still, the focal point is on fiscal 2025&rsquo;s projected sales of $13.34 million. Further, the high-side estimate lands at $42.88 million. Therefore, for the patient speculator, FULC could be one of the under-$10 biotech stocks to buy.</p>



<h2>CorMedix (CRMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715-300x169.png" alt="Biochemical/biotech research scientist team working with microscope"><div>Source: Mongkolchon Akesin / Shutterstock.com</div></div><p>Headquartered in Berkeley Heights, New Jersey, <strong>CorMedix</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/crmd-stock-quote/"><strong>CRMD</strong></a>) is a biopharma firm focusing on the development and commercialization of therapeutic products in the prevention and treatment of infectious and inflammatory diseases. Its lead product candidate is <a href="https://cormedix.com/cormedix-inc-announces-commercial-and-operational-updates/">DefenCath, an antimicrobial catheter lock solution</a> to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.</p>



<p>Although it&rsquo;s one of the riskiest under-$10 biotech stocks, it also enjoys plenty of love on the Street. Analysts rate shares a unanimous strong buy with a $12.67 price target. That implies upside potential of just under 117%. Also, the high-side target hits $19.</p>



<p>For fiscal 2024, experts are looking at a loss per share of 74 cents. That&rsquo;s still in the red but an improvement over last year&rsquo;s loss of 91 cents. On the top line, they&rsquo;re seeking $25.16 million. Last year, the company generated no revenue. Finally, for fiscal 2025, experts are seeking sales of $81.93 million, implying 225.6% YOY growth from projected 2024 revenue.</p>



<p><em>On the date of publication, Josh Enomoto</em><em> did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em><em></em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/04/biotech-on-a-budget-7-stocks-under-10-with-huge-potential/">Biotech on a Budget: 7 Stocks Under $10 With Huge Potential</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential

ACIU

ARQT

ATEC

ATNM

CRMD

LGND

MRNS

OCUL

OTLK

RXRX

Press Releases

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023

Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference

Management

Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fulcrum Therapeutics Stock (NASDAQ:FULC), Short Interest Report

People Also Watch